Evotec announced the launch of a 50:50 joint venture ("JV") with Swiss specialty Pharma company Vifor Pharma AG for the discovery and development of innovative nephrology therapies. The JV combines Evotec's strong expertise in drug discovery with Vifor's proven commercial platform and ambition to become a global leader in nephrology. The aim will be to identify novel targets by leveraging clinical data from a kidney biobank (NURTuRE), reflecting Evotec's patient-centric approach of feeding pa
07 Nov 2019
Nephrology JV with Vifor: patient-centric approach
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Nephrology JV with Vifor: patient-centric approach
Evotec SE (EVT:WBO) | 0 0 0.7% | Mkt Cap: 2,149m
- Published:
07 Nov 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Evotec announced the launch of a 50:50 joint venture ("JV") with Swiss specialty Pharma company Vifor Pharma AG for the discovery and development of innovative nephrology therapies. The JV combines Evotec's strong expertise in drug discovery with Vifor's proven commercial platform and ambition to become a global leader in nephrology. The aim will be to identify novel targets by leveraging clinical data from a kidney biobank (NURTuRE), reflecting Evotec's patient-centric approach of feeding pa